D2MN.F
Duke Energy Corporation
FrankfurtEUREQUITY
Utilities
DELAYED
Last price
103.00
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
103.00
Day high
105.35
Day low
103.00
Volume
1.15K
Market cap
$80.31B
P/E (TTM)
18.10
52W range
97.13 – 117.02
Trailing performance
Returnvs SPY
1W
-3.42%
-2.1%
1M
-9.57%
-13.3%
3M
-4.41%
-7.5%
6M
-5.30%
-16.4%
YTD
+3.35%
-8.9%
1Y
-3.79%
-23.8%
3Y
+23.95%
-50.2%
5Y
+16.49%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on D2MN.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.02M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 18, 26 | CRAVER THEODORE F JR Chairman of the Board |
STOCK | 2.40K | $0 | Direct |
| May 11, 26 | RENJEL LOUIS E Officer |
SELL | 3.50K | $438.02K | Direct |
| May 8, 26 | SIDERIS HARRY K. Chief Executive Officer |
SELL | 20.00K | $2.49M | Direct |
| May 7, 26 | FANANDAKIS NICHOLAS C Director |
STOCK | 1.60K | $200.04K | Direct |
| May 7, 26 | HERRON JOHN T Director |
STOCK | 1.60K | $200.04K | Direct |
| May 7, 26 | DAVIS ROBERT M Director |
STOCK | 1.60K | $200.04K | Direct |
| May 7, 26 | CRAVER THEODORE F JR Chairman of the Board |
STOCK | 2.40K | $299.94K | Direct |
| May 7, 26 | DORSA CAROLINE D Director |
STOCK | 1.60K | $200.04K | Direct |
| Mar 2, 26 | GHARTEY-TAGOE KODWO Officer |
SELL | 18.25K | $2.40M | Direct |
| Mar 2, 26 | REPKO REGIS T Officer |
SELL | 663 | $86.85K | Direct |
| Feb 26, 26 | SIDERIS HARRY K. Chief Executive Officer |
STOCK | 30.54K | $0 | Direct |
| Feb 25, 26 | GILLESPIE THOMAS PRESTON JR. Officer |
STOCK | 5.99K | $0 | Direct |
| Feb 25, 26 | TITONE BONNIE B. Officer |
STOCK | 5.38K | $0 | Direct |
| Feb 25, 26 | WEINTRAUB ALEXANDER J Officer |
STOCK | 2.12K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BATSON SCOTT L. |
Officer | 33.52K | Stock Award(Grant) |
GHARTEY-TAGOE KODWO |
Officer | 52.53K | Sale |
GILLESPIE THOMAS PRESTON JR. |
Officer | 60.57K | Stock Award(Grant) |
GLENN ROBERT ALEXANDER |
Officer | 28.46K | Stock Award(Grant) |
GOOD LYNN J |
Chief Executive Officer | 674.70K | Stock Award(Grant) |
HERRON JOHN T |
Director | 34.52K | Stock Award(Grant) |
JANSON JULIA S. |
Officer | 73.33K | Sale |
SAVOY BRIAN D. |
Chief Financial Officer | 61.76K | Stock Award(Grant) |
SIDERIS HARRY K. |
Chief Executive Officer | 98.64K | Sale |
TITONE BONNIE B. |
Officer | 29.30K | Stock Award(Grant) |
Fundamentals
Market cap$80.31B
Enterprise value$174.93B
Revenue (TTM)$32.80B
Gross profit$17.05B
EBITDA$16.62B
Net income$5.17B
EPS (TTM)$5.69
Free cash flow$-4.48B
Total cash$673.00M
Total debt$92.21B
Book value / share$59.01
Shares outstanding779.70M
Float777.48M
Short % of float—
Dividend yield3.65%
Beta (5Y)0.37
Valuation & profitability ratios
Trailing P/E18.10
Forward P/E18.83
PEG ratio2.40
Price / sales—
Price / book1.75
EV / revenue5.33
EV / EBITDA10.53
Gross margin51.97%
Operating margin27.50%
Profit margin16.00%
Return on equity9.86%
Return on assets2.84%
Debt / equity162.16
Current ratio0.66
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $32.24B | $30.36B | $29.06B | $28.77B | +6.2% |
| Operating revenue | $32.24B | $30.36B | $29.06B | $28.77B | +6.2% |
| Cost of revenue | $15.74B | $15.16B | $15.30B | $15.79B | +3.8% |
| Gross profit | $16.50B | $15.20B | $13.76B | $12.98B | +8.6% |
| Total operating expense | $7.92B | $7.26B | $6.65B | $6.55B | +9.1% |
| Operating income | $8.58B | $7.94B | $7.10B | $6.42B | +8.0% |
| Net interest income | -$3.58B | -$3.32B | -$2.98B | -$2.41B | -7.9% |
| Pre-tax income | $5.71B | $5.19B | $4.77B | $4.08B | +10.0% |
| Tax provision | $642.00M | $590.00M | $438.00M | $300.00M | +8.8% |
| Net income | $4.97B | $4.52B | $2.84B | $2.55B | +9.8% |
| Net income to common | $4.91B | $4.40B | $2.73B | $2.44B | +11.6% |
| Basic EPS | 6.31 | 5.71 | 3.54 | 3.33 | +10.5% |
| Diluted EPS | 6.31 | 5.71 | 3.54 | 3.33 | +10.5% |
| EBIT | $9.35B | $8.58B | $7.78B | $6.52B | +9.0% |
| EBITDA | $17.05B | $15.00B | $13.87B | $12.36B | +13.7% |
| Basic shares | 777.00M | 772.00M | 771.00M | 770.00M | +0.6% |
| Diluted shares | 777.00M | 772.00M | 771.00M | 770.00M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $245.00M | $314.00M | $253.00M | $409.00M | -22.0% |
| Cash & short-term investments | $245.00M | $314.00M | $253.00M | $409.00M | -22.0% |
| Accounts receivable | $4.23B | $4.61B | $4.13B | $4.42B | -8.2% |
| Inventory | $4.57B | $4.50B | $4.29B | $3.58B | +1.6% |
| Total current assets | $11.61B | $12.95B | $12.77B | $13.22B | -10.3% |
| Property, plant & equipment | $131.20B | $122.77B | $116.41B | $112.79B | +6.9% |
| Goodwill & intangibles | $19.01B | $19.01B | $19.30B | $19.30B | 0.0% |
| Total assets | $195.74B | $186.34B | $176.89B | $178.09B | +5.0% |
| Total current liabilities | $21.05B | $19.36B | $17.28B | $18.87B | +8.7% |
| Current debt | $9.73B | $7.93B | $7.09B | $7.83B | +22.6% |
| Long-term debt | $80.11B | $76.34B | $72.45B | $65.87B | +4.9% |
| Total debt | $90.87B | $85.23B | $80.46B | $74.58B | +6.6% |
| Total liabilities | $142.72B | $135.09B | $126.71B | $126.23B | +5.6% |
| Retained earnings | $5.06B | $3.43B | $2.23B | $2.64B | +47.4% |
| Shareholder equity | $51.84B | $50.13B | $49.11B | $49.32B | +3.4% |
| Working capital | -$9.43B | -$6.41B | -$4.51B | -$5.65B | -47.2% |
| Net tangible assets | $32.83B | $31.12B | $29.81B | $30.02B | +5.5% |
| Shares issued | 777.66M | 776.00M | 770.71M | 770.00M | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $5.07B | $4.61B | $2.87B | $2.46B | +9.9% |
| Depreciation & amortisation | $7.70B | $6.42B | $6.08B | $5.84B | +20.0% |
| Change in working capital | -$616.00M | $1.15B | $187.00M | -$3.25B | -153.5% |
| Operating cash flow | $12.33B | $12.33B | $9.88B | $5.93B | +0.0% |
| Capital expenditure | -$14.02B | -$12.28B | -$12.60B | -$11.37B | -14.2% |
| Investing cash flow | -$14.34B | -$13.12B | -$12.47B | -$11.97B | -9.3% |
| Share buybacks | $0 | -$1.00B | $0 | $0 | +100.0% |
| Dividends paid | -$3.30B | -$3.21B | -$3.24B | -$3.18B | -2.7% |
| Financing cash flow | $1.95B | $859.00M | $2.35B | $6.13B | +127.0% |
| Free cash flow | -$1.69B | $48.00M | -$2.73B | -$5.44B | -3,629.2% |
| End cash position | $363.00M | $421.00M | $357.00M | $603.00M | -13.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.59B | $9.18B | $7.94B | $8.54B | $7.51B | -17.3% |
| Operating revenue | $7.59B | $9.18B | $7.94B | $8.54B | $7.51B | -17.3% |
| Cost of revenue | $3.43B | $4.70B | $3.92B | $4.16B | $3.69B | -27.0% |
| Gross profit | $4.16B | $4.48B | $4.02B | $4.38B | $3.82B | -7.1% |
| Total operating expense | $2.07B | $2.14B | $1.92B | $2.06B | $2.00B | -3.1% |
| Operating income | $2.09B | $2.34B | $2.10B | $2.32B | $1.82B | -10.8% |
| Net interest income | -$957.00M | -$968.00M | -$895.00M | -$902.00M | -$897.00M | +1.1% |
| Pre-tax income | $1.30B | $1.90B | $1.36B | $1.63B | $1.13B | -31.2% |
| Tax provision | $160.00M | $333.00M | $154.00M | $176.00M | $119.00M | -52.0% |
| Net income | $1.09B | $1.55B | $1.18B | $1.42B | $984.00M | -29.5% |
| Net income to common | $1.08B | $1.54B | $1.17B | $1.41B | $971.00M | -29.9% |
| Basic EPS | 1.38 | 1.97 | 1.50 | 1.81 | 1.25 | -29.9% |
| Diluted EPS | 1.38 | 1.97 | 1.50 | 1.81 | 1.25 | -29.9% |
| EBIT | $2.26B | $2.87B | $2.30B | $2.53B | $2.02B | -21.0% |
| EBITDA | $4.08B | $4.75B | $4.26B | $4.62B | $3.99B | -14.1% |
| Basic shares | 779.00M | 778.00M | 778.00M | 778.00M | 777.00M | +0.1% |
| Diluted shares | 779.00M | 779.00M | 778.00M | 778.00M | 777.00M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $673.00M | $2.14B | $245.00M | $688.00M | $344.00M | -68.6% |
| Cash & short-term investments | $673.00M | $2.14B | $245.00M | $688.00M | $344.00M | -68.6% |
| Accounts receivable | $4.48B | $3.95B | $4.23B | $4.02B | $4.10B | +13.6% |
| Inventory | $4.67B | $4.57B | $4.57B | $4.49B | $4.43B | +2.0% |
| Total current assets | $13.15B | $13.45B | $11.61B | $12.21B | $12.15B | -2.2% |
| Property, plant & equipment | $136.40B | $133.44B | $131.20B | $127.91B | $127.86B | +2.2% |
| Goodwill & intangibles | $19.01B | $19.01B | $19.01B | $19.01B | $19.30B | 0.0% |
| Total assets | $201.09B | $198.05B | $195.74B | $192.29B | $189.71B | +1.5% |
| Total current liabilities | $19.89B | $20.33B | $21.05B | $19.41B | $18.41B | -2.2% |
| Current debt | $9.00B | $9.77B | $9.73B | $9.34B | $8.52B | -7.9% |
| Long-term debt | $82.24B | $80.48B | $80.11B | $79.30B | $78.91B | +2.2% |
| Total debt | $92.21B | $91.21B | $90.87B | $89.65B | $88.45B | +1.1% |
| Total liabilities | $144.23B | $141.57B | $142.72B | $139.67B | $137.68B | +1.9% |
| Retained earnings | $6.00B | $5.76B | $5.06B | $4.72B | $4.14B | +4.2% |
| Shareholder equity | $54.75B | $54.46B | $51.84B | $51.46B | $50.89B | +0.5% |
| Working capital | -$6.74B | -$6.89B | -$9.43B | -$7.20B | -$6.26B | +2.2% |
| Net tangible assets | $35.74B | $35.45B | $32.83B | $32.45B | $31.59B | +0.8% |
| Shares issued | 780.00M | 778.22M | 777.66M | 777.62M | 778.00M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $1.15B | $1.58B | $1.21B | $1.45B | $1.01B | — | -27.4% |
| Depreciation & amortisation | $1.82B | $1.88B | $1.96B | $2.08B | $1.97B | — | -3.5% |
| Change in working capital | -$545.00M | -$1.76B | $583.00M | $15.00M | -$293.00M | — | +69.1% |
| Operating cash flow | $2.76B | $1.51B | $3.66B | $3.63B | $2.86B | — | +82.5% |
| Capital expenditure | -$4.15B | -$4.09B | -$4.14B | -$3.45B | -$3.28B | — | -1.6% |
| Investing cash flow | -$4.36B | -$1.85B | -$4.36B | -$3.71B | -$2.96B | — | -136.3% |
| Share buybacks | — | — | $0 | — | — | $0 | — |
| Dividends paid | -$847.00M | -$846.00M | -$845.00M | -$845.00M | -$807.00M | — | -0.1% |
| Financing cash flow | $201.00M | $2.22B | $328.00M | $377.00M | $7.00M | — | -91.0% |
| Free cash flow | -$1.39B | -$2.58B | -$485.00M | $179.00M | -$417.00M | — | +46.0% |
| End cash position | $850.00M | $2.25B | $363.00M | $739.00M | $442.00M | — | -62.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $8.91B | +4.3% |
| Next quarter | — | — | $8.03B | +1.1% |
| Current year | — | — | $33.74B | +4.7% |
| Next year | — | — | $35.28B | +4.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.13%
Held by institutions71.11%
Institutions holding3.01K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
105.95
-2.79% from price
SMA 20
108.02
-4.65% from price
SMA 50
109.71
-6.12% from price
SMA 100
108.92
-5.43% from price
SMA 200
107.20
-3.91% from price
EMA 12
106.33
-3.13% from price
EMA 26
107.81
-4.46% from price
EMA 50
108.61
-5.17% from price
RSI (14)
35.0
Neutral
MACD (12,26,9)
-1.48
Hist -0.34
ATR (14)
1.56
1.51% of price
Realised vol 30D
22.9%
Annualised
Bollinger upper
114.72
20, 2σ
Bollinger lower
101.32
20, 2σ
50 / 200 cross
Golden
109.71 vs 107.20
Trend bias
Below 200
-3.91%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.23
Less volatile than market
Correlation to SPY
-0.16
Largely independent
Realised vol 30D
22.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-12.4%
Peak to trough
Max drawdown 5Y
-28.7%
Peak to trough
ATR 14
1.56
1.51% of price
Beta (reported)
0.37
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 17, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 5, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 23, 26 | Keybanc | UPGRADE | Sector Weight | Overweight |
| Jul 20, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Jul 17, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 16, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Jun 18, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jun 18, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 18, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 13, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate$3.76 / yr
Forward yield3.65%
5-year avg yield3.82%
Payout ratio64.16%
Ex-dividend dateAug 14, 2026
Next pay date—
Last split1:3
Split dateJul 2, 2012
Headlines
TME Pharma provides update on its activities
GlobeNewswire · 10m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 15m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 15m ago
Board Update
GlobeNewswire · 15m ago
Aegon implements EUR 150 million increase in share buyback program
GlobeNewswire · 15m ago
TOMY's "TOMICA XROSS RESCUE" Diorama-based Short Animation Series to Begin Streaming Aug. 26, 2026
PR Newswire · 15m ago
Holding(s) in Company
GlobeNewswire · 15m ago
Summary of AB KN Energies webinar
GlobeNewswire · 15m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.